Abstract Number: 0891 • ACR Convergence 2022
Rheumatoid Arthritis and the Rheumatic Disease Comorbidity Index (RDCI): Its Impact on Disease Activity
Background/Purpose: Comorbid conditions in the setting of rheumatoid arthritis (RA) play an important role in predicting disease activity and functional impairment (1). Application of a…Abstract Number: 0907 • ACR Convergence 2022
Identifying Trajectories of Remission in Patients with Rheumatoid Arthritis Treated in a Tertiary Care Centre
Background/Purpose: The main goal of treatment for patients (pts) with rheumatoid arthritis (RA) is remission to preserve physical function and prevent radiographic damage. However, less…Abstract Number: 0923 • ACR Convergence 2022
Identification of Cell-Specific DNA Methylation Changes Associated with MTX Treatment Response in Rheumatoid Arthritis
Background/Purpose: MTX is the recommended first treatment for rheumatoid arthritis (RA); however, only ~40% respond adequately to MTX. Significant joint damage can occur in the…Abstract Number: 0981 • ACR Convergence 2022
QTc Prolongation in Rheumatoid Arthritis and Systemic Lupus Erythematosus Patients Treated with Hydroxychloroquine – Preliminary Results from a Single Center Study
Background/Purpose: The effect of hydroxychloroquine (HCQ) on QTc interval in patients with rheumatic diseases is under scrutiny since the COVID-19 pandemic, however studies have shown…Abstract Number: 1196 • ACR Convergence 2022
Interaction of Cumulative Inflammation with Smoking and Lipids in Risk Modification of Dementia Among Patients with Rheumatoid Arthritis: A Population-based Cohort Study
Background/Purpose: Patients with rheumatoid arthritis (RA) have increased risk of developing dementia. Systemic inflammation is implicated in the pathogenesis of cognitive decline. However, the association…Abstract Number: 1270 • ACR Convergence 2022
MDHAQ/RAPID3 Is a Feasible Tool to Estimate High Comorbid Fatigue and Residual Fatigue in Rheumatoid Arthritis Patients
Background/Purpose: Fatigue is a major symptom for rheumatoid arthritis (RA) patients with a high prevalence (40%-70%)1 measured by different validated questionnaires and scales. A 0-10…Abstract Number: 1391 • ACR Convergence 2022
Inadequate Cardiovascular Disease Risk Screening and Preventative Treatment in Patients with Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease. Patients with RA are at risk of accelerated cardiovascular disease (CVD). The purpose of this study…Abstract Number: 1407 • ACR Convergence 2022
Longitudinal Lipid Profile and NT-proBNP Changes from Pre-clinical to Established Rheumatoid Arthritis: A 12 Years Follow up Explorative Study
Background/Purpose: Patients with rheumatoid arthritis (RA) have an increased risk for developing cardiovascular diseases (CVD). This is partly due to the systemic inflammation characteristic to…Abstract Number: 1425 • ACR Convergence 2022
Treatment Persistence and Switching Patterns of ABP 501 (AMGEVITA®) in German Patients with Rheumatic Diseases
Background/Purpose: ABP 501 is the first adalimumab (ADA) biosimilar approved by the European Medical Association and the Food and Drug Administration for the treatment of…Abstract Number: 1589 • ACR Convergence 2022
Multiple Switching Between the Biosimilar Adalimumab PF-06410293 (Abrilada™) and Reference Adalimumab (Humira®)in Combination with Methotrexate in Patients with Moderately to Severely Active Rheumatoid Arthritis
Background/Purpose: PF-06410293 (ADL-afzb) is an adalimumab (ADL) biosimilar approved in the US, the EU, and 19 other countries. Biosimilarity of ADL-afzb with reference ADL (ADL-REF)…Abstract Number: 1650 • ACR Convergence 2022
Systemic Immune Inflammation Index Predict All-Cause and Cardiovascular Mortality in Rheumatoid Arthritis
Background/Purpose: The systemic immune inflammation index (SII) is an inflammation-based biomarker that is an influential prognostic factor in diseases with an inflammation-related etiology. This index…Abstract Number: 1749 • ACR Convergence 2022
Mass Spectrometry-Based HLA Peptidomics Analysis Reveals Both Expected and Novel Citrullinated Antigen Targets in Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease in which citrullinated self-antigens are recognized by anti-citrullinated protein antibodies (ACPA) and T cells. ACPA are a…Abstract Number: 1950 • ACR Convergence 2022
Morbidities Associated with Serious Infections in Patients with Rheumatoid Arthritis
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk for serious infections. Several infection risk scores have been developed over the last decade for…Abstract Number: 1966 • ACR Convergence 2022
Favorable Effects of TNF Inhibitors on Intima Media Thickness and Arterial Stiffness in Rheumatoid Arthritis: A Systematic Review and Meta-analysis
Background/Purpose: Controlling inflammation with tumour necrosis factor (TNF) inhibitors in rheumatoid arthritis (RA) patients is hypothesized to reduce their cardiovascular risk. Arterial wall thickness (carotid…Abstract Number: 1984 • ACR Convergence 2022
Malignancies Risk in Rheumatoid Arthritis Patients Treated with Tofacitinib or TNF Inhibitors, a National Study: RELATION Study
Background/Purpose: Patients with IMID, and notably patients with rheumatoid arthritis RA, are at increased risk of cancer compared with the general population. It is hence…
- « Previous Page
- 1
- …
- 96
- 97
- 98
- 99
- 100
- …
- 188
- Next Page »